Market Overview

BioCryst Initiates Phase 2a Clinical Trial of BCX4161 in Patients with Hereditary Angioedema

BioCryst
Pharmaceuticals (NASDAQ: BCRX) today announced that it has
dosed the first subject in OPuS-1 (Oral ProphylaxiS-1),
a Phase 2a proof of concept clinical trial of orally-administered BCX4161
in patients with hereditary angioedema (HAE).

The OPuS-1 trial will test 400 mg of BCX4161 administered three times
daily for 28 days in up to 25 HAE patients who have a high frequency of
attacks (≥ 1 per week), in a randomized, placebo-controlled, two-period
cross-over design. The main goals for the OPuS-1 trial are to estimate
BCX4161's degree of efficacy in reducing the frequency of angioedema
attacks, and to evaluate the safety and tolerability of 28 days of
BCX4161 treatment.

See full press release

Posted-In: News Guidance Offerings Contracts Asset Sales FDA Management Global

 

Related Articles (BCRX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters